TanCART19/20

N/A

Report date: 2021/12/14 16:37:33

Base Information

Drug NameTanCART19/20

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsAnti-CD20T lymphocyte replacements

TargetsB-lymphocyte antigen CD19B-lymphocyte antigen CD20

Therapy Area/IndicationsNeuromyelitis Optica

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesPla General Hospital

China Registration ClassN/A

Develop Information

Active CompaniesPla General Hospital

Inactive CompaniesN/A

Active IndicationsNeuromyelitis Optica

Inactive IndicationsN/A

Other Information

ATC CodeN/A